TRAM
REGN icon

Tuscan Ridge Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Tuscan Ridge Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-12,505
Closed -$3.47M – 476
2019
Q3 		$3.47M Sell
12,505
-1,200
-9% -$355K 0.19% 161
2019
Q2 		$4.29M Buy
13,705
+9,305
+211% +$3.1M 0.33% 77
2019
Q1 		$1.81M Buy
+4,400
New +$1.81M 0.13% 208

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Tuscan Ridge Asset Management's REGN Position: Q4 2019 in Review

Tuscan Ridge Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2019, closing a stake of 12,505 shares — an estimated $3.47M sold.

Tuscan Ridge Asset Management first reported a position in REGN in Q1 2019 and held it in 3 quarters. The position peaked at $4.29M in Q2 2019. 702 funds tracked by Wall St. Rank hold REGN as of Q4 2019.

  • Tuscan Ridge Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Tuscan Ridge Asset Management sold 12,505 Regeneron Pharmaceuticals shares in Q4 2019, an estimated $3.47M.
  • Tuscan Ridge Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Tuscan Ridge Asset Management's Regeneron Pharmaceuticals position peaked at $4.29M in Q2 2019.
  • 702 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2019.

Based on Tuscan Ridge Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.